Alpha 2.0
Login Register
» Authors » Simona Di Giambenedetto

Simona Di Giambenedetto

Explore the profile of Simona Di Giambenedetto including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 232
Citations 1815
Followers 0
Related Specialties
Infectious Diseases
Microbiology
Pharmacology
Top 10 Co-Authors
Alberto Borghetti
Andrea De Luca
Arturo Ciccullo
Roberto Cauda
Massimiliano Fabbiani
Francesca Lombardi
Gianmaria Baldin
Manuela Colafigli
Stefano Rusconi
Andrea Antinori
Published In
J Antimicrob Chemother
Antivir Ther
J Acquir Immune Defic Syndr
AIDS Res Hum Retroviruses
AIDS
Affiliations
Soon will be listed here.
Recent Articles
1.
Assessing dengue seroprevalence among people living with HIV (PLWH) in Rome, Italy: insights from the 2023 Italian autochthonous outbreak
Salvo P, Lombardi F, Sanfilippo A, Iannone V, Baldin G, Borghetti A, et al.
Travel Med Infect Dis . 2025 Mar; :102832. PMID: 40068726
Background: Global warming has facilitated the spread of mosquito-borne diseases, including dengue, to non-endemic areas like Italy. People living with HIV (PLWH) are at increased risk of severe dengue, especially...
2.
'With age comes wisdom': effectiveness and tolerability of dolutegravir + lamivudine in virologically-suppressed people with HIV
Baldin G, Salvo P, Passerotto R, Iannone V, Lamanna F, Carbone A, et al.
AIDS . 2025 Feb; PMID: 39945629
Objectives: Results from clinical trials and observational studies suggest that dolutegravir plus lamivudine is a well tolerated option for simplification in people with HIV (PWH). We aimed to assess long-time...
3.
Impact of HBV serological status on HIV virological efficacy of two-drug antiretroviral regimens: A retrospective observational study on virologically suppressed people with HIV switching to lamivudine/dolutegravir
Salvo P, Ciccullo A, Visconti E, Lombardi F, Torti C, Di Giambenedetto S, et al.
HIV Med . 2025 Feb; PMID: 39907097
Objectives: This study aimed to evaluate the HIV virological efficacy of two-drug regimens (2DR) with lamivudine (3TC) and dolutegravir (DTG) in people with HIV (PWH), classified by their hepatitis B...
4.
Unconventional use of injectable long-acting cabotegravir and rilpivirine against HIV-1 in PWH in clinical need: 52 weeks real-world data
Iannone V, Rossotti R, Bana N, Cavazza G, DAmico F, Lombardi F, et al.
BMC Infect Dis . 2025 Jan; 25(1):105. PMID: 39844075
Background: Long-acting Cabotegravir and Rilpivirine (LA CAB + RPV) shows potential advantages in heavily comorbid and even in viremic people with HIV (PWH). We assessed LA CAB + RPV durability...
5.
Factors associated with oxidative stress in virologically suppressed people living with HIV on long-term antiretroviral therapy
Lombardi F, Belmonti S, Sanfilippo A, Borghetti A, Iannone V, Salvo P, et al.
AIDS Res Ther . 2024 Dec; 21(1):100. PMID: 39734213
Background: Oxidative stress (OS) is the imbalance between oxidant and antioxidant molecules, in favour of oxidants, that has been associated with an increased risk of morbidity and mortality in ART-treated...
6.
Association among therapeutic adherence, health literacy, and engagement in care: How to increase health-conscious management of HIV disease
Massaroni V, Delle Donne V, Salvo P, Farinacci D, Iannone V, Baldin G, et al.
Int J STD AIDS . 2024 Nov; 36(2):132-140. PMID: 39499018
Background: In the context of People Living with HIV (PLWH), poor health literacy (HL) seems to be linked to poorer health outcomes and reduced engagement in care. Additionally, the level...
7.
Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: a real life multicentre cohort
Ciccullo A, Baldin G, Cervo A, Moschese D, Lagi F, Cossu M, et al.
J Antimicrob Chemother . 2024 Oct; 80(1):175-177. PMID: 39478330
Objectives: We compared the effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) and dolutegravir plus lamivudine (DTG + 3TC) in our cohort of treatment-naive people with HIV (PWH). Methods: In...
8.
Cardiovascular Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Virologically Suppressed PLWHIV: A Comparative Analysis of CVD Scores
Ciccullo A, Iannone V, Farinacci D, Steiner R, Lombardi F, Carbone A, et al.
AIDS Res Hum Retroviruses . 2024 Oct; 41(2):87-89. PMID: 39470362
The Aim of this study is to assess the cardiovascular safety of doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF). We analyzed data from 37 virologically suppressed people living with HIV starting DOR/3TC/TDF, collecting...
9.
Investigating seroprevalence of IgG antibodies against Monkeypox Virus (MPXV) in a cohort of people living with HIV (PLWH) in Rome, during the 2022 outbreak: Moving beyond traditional at-risk populations
Salvo P, Sanfilippo A, Baldin G, Iannone V, Ciccullo A, Farinacci D, et al.
Travel Med Infect Dis . 2024 Sep; 62:102757. PMID: 39241937
Background: High incidence mpox rates suggest asymptomatic individuals may contribute to virus transmission. We undertook this study to assess the seroprevalence of IgG anti-MPXV in a cohort of asymptomatic PLWH,...
10.
Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study
Kumar P, Clarke A, Jonsson-Oldenbuttel C, Garcia Deltoro M, Di Giambenedetto S, Brites C, et al.
AIDS Behav . 2024 Sep; 29(1):235-245. PMID: 39225890
Patient-reported outcomes (PROs) facilitate communication between patients and providers, enhancing patient-centered care. We report PROs for virologically suppressed people living with HIV-1 who switched to dolutegravir/lamivudine (DTG/3TC) or continued their...